25 Results for "

human CD73

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "human CD73" in MCE Product Catalog:

Cat. No.: HY-P77534
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: NT5E; ENT; Prev. NT5; 5'-NT; IMP-Specific 5'-Nucleotidase; NTE; Thymidylate 5'-Phosphatase; 5'-Nucleotidase, Ecto (CD73); 5'-Deoxynucleotidase; Purine 5-Prime-Nucleotidase; Ecto-5'-Nucleotidase; 5' Nucleotidase (CD73); 5'-Nucleotidase; CD73 Antigen; CALJA
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-100747R
CAS No.: 1802226-78-3
Research Areas:  

Cancer

PSB-12379 (Standard) is the analytical standard of PSB-12379 (HY-100747). This product is intended for research and analytical applications. PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human) .
loading...
    loading...
Cat. No.: HY-188081
CAS No.: 3112733-78-2
Research Areas:  

Cancer

YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-184969
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-183620
Target:  

NTPDase CD73

Research Areas:  

Cancer

PSB-24379 is a CD39 inhibitor that potently inhibits human membrane-bound CD39 (Ki = 77.4 nM) and truncated soluble human CD39 (Ki = 23.1 nM). PSB-24379 reduces the level of ATP hydrolysis in melanoma and breast cancer cell membranes. PSB-24379 partially reverses ATP-mediated suppression of T cell activation and proliferation in a high-ATP environment. PSB-24379 can be used in research related to melanoma and breast cancer .
loading...
    loading...